Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

bio products laboratory ltd - von willebrand factor; factor viii - powder and solvent for solution for infusion - 860unit ; 500unit

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

bio products laboratory ltd - von willebrand factor; factor viii - powder and solvent for solution for infusion - 1720unit ; 1000unit

Malezya - İngilizce - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaniaga marketing sdn bhd - coagulation factor viii; von willebrand factor -

Malezya - İngilizce - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaniaga marketing sdn bhd - coagulation factor viii; von willebrand factor -

ABD - İngilizce - NLM (National Library of Medicine)

octapharma pharmazeutika produktionsgesellschaft m.b.h. - antihemophilic factor human (unii: 839moz74gk) (antihemophilic factor human - unii:839moz74gk), von willebrand factor human (unii: ze22ne22f1) (von willebrand factor human - unii:ze22ne22f1) - antihemophilic factor human 100 [iu] in 1 ml - wilate is a von willebrand factor/coagulation factor viii complex (human) indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von willebrand disease (vwd) as well as patients with mild or moderate vwd in whom the use of desmopressin is known or suspected to be ineffective or contraindicated. clinical trials to evaluate the safety and efficacy of prophylactic dosing with wilate to prevent spontaneous bleeding have not been conducted in vwd subjects. wilate is not indicated for the prevention of excessive bleeding during and after surgery in vwd patients. wilate is not indicated for hemophilia a. wilate is contraindicated for patients who have known anaphylactic or severe systemic reaction to plasma-derived products, any ingredient in the formulation, or components of the container. for a complete listing of ingredients, see description ( 11 ). pregnancy category c. animal reproduction studies have not been conducted with wilate. it is also not known whether

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu; von willebrand factor, quantity: 1000 iu - injection, solution - excipient ingredients: water for injections - aleviate? is indicated for: ? the prophylaxis and treatment of non surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated ? the prophylaxis and treatment of non surgical and surgical bleeding associated with fviii deficiency due to haemophilia a.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - aleviate? is indicated for: ? the prophylaxis and treatment of non surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated ? the prophylaxis and treatment of non surgical and surgical bleeding associated with fviii deficiency due to haemophilia a.

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - factor viii, human recombinant - powder and solvent for solution for injection - 1000 iu international unit(s) - blood coagulation factors; coagulation factor viii - antihaemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this product does not contain von willebrand factor and is therefore not indicated in von willebrand’s disease

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - factor viii, human recombinant - powder and solvent for solution for injection - 500 iu international unit(s) - blood coagulation factors; coagulation factor viii - antihaemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this product does not contain von willebrand factor and is therefore not indicated in von willebrand’s disease.

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - factor viii, human recombinant - powder and solvent for solution for injection - 250 iu international unit(s) - blood coagulation factors; coagulation factor viii - antihaemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this product does not contain von willebrand factor and is therefore not indicated in von willebrand’s disease.